$SYRE
Spyre Therapeutics, Inc.

2024 Q4 Form 10-Q Financial Statement

#000163628224000083 Filed on November 07, 2024

View on sec.gov

Income Statement

Concept 2024 Q4 2024 Q3 2023 Q3
Revenue $0.00 $0.00
YoY Change -100.0%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $10.65M $8.580M
YoY Change 24.1% 23.42%
% of Gross Profit
Research & Development $44.74M $24.66M
YoY Change 81.44% 105.89%
% of Gross Profit
Depreciation & Amortization $0.00 $0.00
YoY Change -100.0%
% of Gross Profit
Operating Expenses $55.39M $18.34M
YoY Change 202.08% -3.13%
Operating Profit -$55.39M -$18.34M
YoY Change 202.08% -2.23%
Interest Expense $5.184M -$24.11M
YoY Change -121.5% -8471.53%
% of Operating Profit
Other Income/Expense, Net -$13.62M -$21.77M
YoY Change -37.44% -7076.6%
Pretax Income -$69.01M -$40.10M
YoY Change 72.08% 117.45%
Income Tax $18.00K $3.000K
% Of Pretax Income
Net Earnings -$69.03M -$40.11M
YoY Change 72.11% 119.96%
Net Earnings / Revenue
Basic Earnings Per Share -$1.36 -$9.34
Diluted Earnings Per Share -$1.36 -$9.34
COMMON SHARES
Basic Shares Outstanding 51.43M shares 50.79M shares 101.2M
Diluted Shares Outstanding 50.89M shares 4.294M shares

Balance Sheet

Concept 2024 Q4 2024 Q3 2023 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $414.2M $203.6M
YoY Change 103.45% 176.34%
Cash & Equivalents $71.58M $90.59M
Short-Term Investments $342.6M $113.0M
Other Short-Term Assets $6.852M $2.200M
YoY Change 211.45% -72.06%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $421.1M $205.9M
YoY Change 104.46% 150.49%
LONG-TERM ASSETS
Property, Plant & Equipment $0.00
YoY Change -100.0%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $10.00K $9.000K
YoY Change 11.11% -98.8%
Total Long-Term Assets $10.00K $1.316M
YoY Change -99.24% -85.92%
TOTAL ASSETS
Total Short-Term Assets $421.1M $205.9M
Total Long-Term Assets $10.00K $1.316M
Total Assets $421.1M $207.3M
YoY Change 103.16% 126.36%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $19.65M $21.50M
YoY Change -8.62% 414.6%
Accrued Expenses $13.15M $15.90M
YoY Change -17.28% 22.35%
Deferred Revenue $0.00
YoY Change -100.0%
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $57.54M $44.87M
YoY Change 28.23% 153.83%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities $36.16M $20.70M
YoY Change 74.69%
Total Long-Term Liabilities $36.16M $20.70M
YoY Change 74.69%
TOTAL LIABILITIES
Total Short-Term Liabilities $57.54M $44.87M
Total Long-Term Liabilities $36.16M $20.70M
Total Liabilities $93.70M $65.56M
YoY Change 42.92% 173.05%
SHAREHOLDERS EQUITY
Retained Earnings -$916.1M -$701.2M
YoY Change 30.65% 72.37%
Common Stock $1.086B $456.0M
YoY Change 138.23% -3.91%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $327.4M -$245.4M
YoY Change
Total Liabilities & Shareholders Equity $421.1M $207.3M
YoY Change 103.16% 126.36%

Cashflow Statement

Concept 2024 Q4 2024 Q3 2023 Q3
OPERATING ACTIVITIES
Net Income -$69.03M -$40.11M
YoY Change 72.11% 119.96%
Depreciation, Depletion And Amortization $0.00 $0.00
YoY Change -100.0%
Cash From Operating Activities -$29.42M -$34.59M
YoY Change -14.94% 129.56%
INVESTING ACTIVITIES
Capital Expenditures $0.00
YoY Change -100.0%
Acquisitions
YoY Change
Other Investing Activities $42.74M -$97.63M
YoY Change -143.78% -691.7%
Cash From Investing Activities $42.74M -$97.63M
YoY Change -143.78% -691.73%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 12.78M -12.53M
YoY Change -202.0% 9538.46%
NET CHANGE
Cash From Operating Activities -29.42M -34.59M
Cash From Investing Activities 42.74M -97.63M
Cash From Financing Activities 12.78M -12.53M
Net Change In Cash 26.10M -144.8M
YoY Change -118.03% -11226.06%
FREE CASH FLOW
Cash From Operating Activities -$29.42M -$34.59M
Capital Expenditures $0.00
Free Cash Flow -$34.59M
YoY Change 129.57%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Central Index Key
EntityCentralIndexKey
0001636282
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2024-09-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity Registrant Name
EntityRegistrantName
SPYRE THERAPEUTICS, INC.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
46-4312787
dei Entity Address Address Line1
EntityAddressAddressLine1
221 Crescent Street
dei Entity Address Address Line2
EntityAddressAddressLine2
Building 23
dei Entity Address Address Line3
EntityAddressAddressLine3
Suite 105
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
0 usd
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
886000 usd
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-69.57
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-69.57
CY2024Q1 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
8385000 usd
CY2024Q1 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
16000 usd
CY2024Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-681000 usd
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-43857000 usd
us-gaap Net Income Loss
NetIncomeLoss
-275610000 usd
us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
37000 usd
us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
-1000 usd
CY2023Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-114000 usd
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
1118000 usd
CY2024Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-67018000 usd
CY2023Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-40250000 usd
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-150567000 usd
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-83000 usd
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
dei Entity Address City Or Town
EntityAddressCityOrTown
Waltham
dei Entity Address State Or Province
EntityAddressStateOrProvince
MA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
02453
dei City Area Code
CityAreaCode
617
dei Local Phone Number
LocalPhoneNumber
651-5940
dei Security12b Title
Security12bTitle
Common Stock, $0.0001 Par Value Per Share
dei Trading Symbol
TradingSymbol
SYRE
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Shell Company
EntityShellCompany
false
CY2024Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
71580000 usd
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
188893000 usd
CY2024Q3 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
342647000 usd
CY2023Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
150384000 usd
CY2024Q3 us-gaap Assets Current
AssetsCurrent
421079000 usd
CY2024Q3 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
0 usd
CY2023Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
322000 usd
CY2024Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
10000 usd
CY2023Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
9000 usd
CY2023Q4 us-gaap Assets
Assets
341859000 usd
CY2024Q3 us-gaap Accounts Payable Trade Current
AccountsPayableTradeCurrent
5165000 usd
CY2023Q4 us-gaap Accounts Payable Trade Current
AccountsPayableTradeCurrent
896000 usd
CY2024Q3 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
24740000 usd
CY2023Q4 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
1390000 usd
CY2024Q3 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
13153000 usd
CY2023Q4 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
13108000 usd
CY2024Q3 us-gaap Liabilities Current
LiabilitiesCurrent
57539000 usd
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
31978000 usd
CY2024Q3 us-gaap Derivative Liabilities Noncurrent
DerivativeLiabilitiesNoncurrent
36160000 usd
CY2023Q4 us-gaap Derivative Liabilities Noncurrent
DerivativeLiabilitiesNoncurrent
41310000 usd
CY2024Q3 us-gaap Liabilities
Liabilities
93699000 usd
CY2023Q4 us-gaap Liabilities
Liabilities
73288000 usd
CY2024Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2023Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2024Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
6852000 usd
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2251000 usd
CY2023Q4 us-gaap Assets Current
AssetsCurrent
341528000 usd
CY2024Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2024Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
400000000 shares
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
400000000 shares
CY2024Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
51395608 shares
CY2024Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
51395608 shares
CY2024Q3 us-gaap Common Stock Value
CommonStockValue
12000 usd
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
10000 usd
CY2024Q3 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
1086237000 usd
CY2023Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
763191000 usd
CY2024Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
1457000 usd
CY2023Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
302000 usd
CY2024Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-916136000 usd
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-764414000 usd
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
184016000 usd
CY2024Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
421089000 usd
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
341859000 usd
CY2024Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
0 usd
CY2023Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
0 usd
CY2024Q3 us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
44744000 usd
CY2023Q3 us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
24660000 usd
us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
112308000 usd
us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
55822000 usd
CY2024Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
10648000 usd
CY2023Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
8584000 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
35005000 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
25874000 usd
CY2024Q3 syre Acquired In Process Research And Development
AcquiredInProcessResearchAndDevelopment
0 usd
CY2023Q3 syre Acquired In Process Research And Development
AcquiredInProcessResearchAndDevelopment
-298000 usd
syre Acquired In Process Research And Development
AcquiredInProcessResearchAndDevelopment
0 usd
syre Acquired In Process Research And Development
AcquiredInProcessResearchAndDevelopment
130188000 usd
CY2024Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
50889433 shares
CY2024Q3 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
6955000 usd
CY2024Q3 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
17000 usd
CY2024Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
1993000 usd
dei Amendment Flag
AmendmentFlag
false
CY2024Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
51431220 shares
CY2024Q3 us-gaap Assets
Assets
421089000 usd
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
36057109 shares
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
36057109 shares
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
327390000 usd
CY2024Q3 us-gaap Disposal Group Not Discontinued Operation Gain Loss On Disposal
DisposalGroupNotDiscontinuedOperationGainLossOnDisposal
0 usd
CY2023Q3 us-gaap Disposal Group Not Discontinued Operation Gain Loss On Disposal
DisposalGroupNotDiscontinuedOperationGainLossOnDisposal
14609000 usd
us-gaap Disposal Group Not Discontinued Operation Gain Loss On Disposal
DisposalGroupNotDiscontinuedOperationGainLossOnDisposal
0 usd
us-gaap Disposal Group Not Discontinued Operation Gain Loss On Disposal
DisposalGroupNotDiscontinuedOperationGainLossOnDisposal
14609000 usd
CY2024Q3 us-gaap Operating Expenses
OperatingExpenses
55392000 usd
CY2023Q3 us-gaap Operating Expenses
OperatingExpenses
18337000 usd
us-gaap Operating Expenses
OperatingExpenses
147313000 usd
us-gaap Operating Expenses
OperatingExpenses
197275000 usd
CY2024Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-55392000 usd
CY2023Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-18337000 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-147313000 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-196389000 usd
CY2024Q3 us-gaap Investment Income Net
InvestmentIncomeNet
5184000 usd
CY2023Q3 us-gaap Investment Income Net
InvestmentIncomeNet
1251000 usd
us-gaap Investment Income Net
InvestmentIncomeNet
15536000 usd
us-gaap Investment Income Net
InvestmentIncomeNet
2021000 usd
CY2024Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-18802000 usd
CY2023Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
2342000 usd
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-19895000 usd
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
2262000 usd
CY2024Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-13618000 usd
CY2023Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-21767000 usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-4359000 usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-79247000 usd
CY2024Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-69010000 usd
CY2023Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-40104000 usd
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-151672000 usd
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-275636000 usd
CY2024Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
18000 usd
CY2023Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
3000 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
50000 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-26000 usd
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-69028000 usd
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-40107000 usd
us-gaap Net Income Loss
NetIncomeLoss
-151722000 usd
us-gaap Net Income Loss
NetIncomeLoss
-275610000 usd
CY2024Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.36
CY2024Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.36
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-9.34
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-9.34
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-3.43
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-3.43
CY2024Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
50889433 shares
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
4293812 shares
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
4293812 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
44263746 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
44263746 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
3961546 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
3961546 shares
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-69028000 usd
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-40107000 usd
us-gaap Net Income Loss
NetIncomeLoss
-151722000 usd
CY2024Q3 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
17000 usd
CY2023Q3 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
-29000 usd
CY2024Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
1993000 usd
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-275694000 usd
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
184016000 usd
CY2024Q1 syre Stock Issued During Period Value Options Exercised And Employee Stock Ownership Plan
StockIssuedDuringPeriodValueOptionsExercisedAndEmployeeStockOwnershipPlan
4390000 usd
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
152269000 usd
CY2024Q2 syre Stock Issued During Period Value Conversion Of Convertible Securities Resulting From Shareholder Approval
StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesResultingFromShareholderApproval
253405000 usd
CY2024Q2 syre Stock Issued During Period Value Exchange Of Convertible Securities
StockIssuedDuringPeriodValueExchangeOfConvertibleSecurities
0 usd
CY2024Q2 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
0 usd
CY2024Q2 syre Stock Issued During Period Value Options Exercised In Connection With Warrants
StockIssuedDuringPeriodValueOptionsExercisedInConnectionWithWarrants
1000 usd
CY2024Q2 syre Stock Issued During Period Value Options Exercised And Employee Stock Ownership Plan
StockIssuedDuringPeriodValueOptionsExercisedAndEmployeeStockOwnershipPlan
494000 usd
CY2024Q2 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
7243000 usd
CY2024Q2 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
4000 usd
CY2024Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-194000 usd
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-38837000 usd
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
374385000 usd
CY2024Q3 syre Stock Issued During Period Value At The Market Offerings Net
StockIssuedDuringPeriodValueAtTheMarketOfferingsNet
11750000 usd
CY2024Q3 syre Stock Issued During Period Value Options Exercised And Employee Stock Ownership Plan
StockIssuedDuringPeriodValueOptionsExercisedAndEmployeeStockOwnershipPlan
1318000 usd
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-69028000 usd
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
327390000 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
50305000 usd
CY2023Q1 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
18000 usd
CY2023Q1 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
1709000 usd
CY2023Q1 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
10000 usd
CY2023Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
32000 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-18422000 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
33652000 usd
CY2023Q2 us-gaap Stock Issued During Period Value Acquisitions
StockIssuedDuringPeriodValueAcquisitions
3768000 usd
CY2023Q2 syre Contingent Value Right Distribution To Common Stockholders
ContingentValueRightDistributionToCommonStockholders
-29500000 usd
CY2023Q2 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
1775000 usd
CY2023Q2 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
18000 usd
CY2023Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-1000 usd
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-217081000 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
-207369000 usd
CY2023Q3 us-gaap Stock Issued During Period Value Purchase Of Assets
StockIssuedDuringPeriodValuePurchaseOfAssets
0 usd
CY2023Q3 syre Stock Issued During Period Value Options Exercised And Employee Stock Ownership Plan
StockIssuedDuringPeriodValueOptionsExercisedAndEmployeeStockOwnershipPlan
105000 usd
CY2023Q3 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
2112000 usd
CY2023Q3 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
-29000 usd
CY2023Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-114000 usd
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-40107000 usd
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
-245402000 usd
us-gaap Profit Loss
ProfitLoss
-151722000 usd
us-gaap Profit Loss
ProfitLoss
-275610000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
35617000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
8405000 usd
syre Acquired In Process Research And Development
AcquiredInProcessResearchAndDevelopment
0 usd
syre Acquired In Process Research And Development
AcquiredInProcessResearchAndDevelopment
130188000 usd
us-gaap Disposal Group Not Discontinued Operation Gain Loss On Disposal
DisposalGroupNotDiscontinuedOperationGainLossOnDisposal
0 usd
us-gaap Disposal Group Not Discontinued Operation Gain Loss On Disposal
DisposalGroupNotDiscontinuedOperationGainLossOnDisposal
14609000 usd
us-gaap Asset Impairment Charges
AssetImpairmentCharges
0 usd
us-gaap Asset Impairment Charges
AssetImpairmentCharges
2580000 usd
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
0 usd
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-915000 usd
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
8985000 usd
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
612000 usd
syre Interest Proceeds Debt Securities
InterestProceedsDebtSecurities
581000 usd
syre Interest Proceeds Debt Securities
InterestProceedsDebtSecurities
0 usd
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
0 usd
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
744000 usd
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
0 usd
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
220000 usd
us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
0 usd
us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-18000 usd
us-gaap Increase Decrease In Accounts Payable Trade
IncreaseDecreaseInAccountsPayableTrade
4268000 usd
us-gaap Increase Decrease In Accounts Payable Trade
IncreaseDecreaseInAccountsPayableTrade
1001000 usd
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
-257000 usd
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
-4000000 usd
us-gaap Increase Decrease In Other Accounts Payable
IncreaseDecreaseInOtherAccountsPayable
-15138000 usd
us-gaap Increase Decrease In Other Accounts Payable
IncreaseDecreaseInOtherAccountsPayable
-2115000 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
4205000 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-3310000 usd
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
0 usd
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
575000 usd
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
0 usd
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-212000 usd
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
0 usd
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-2326000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-120211000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-68874000 usd
us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
183419000 usd
us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
21000000 usd
us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
366160000 usd
us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
112631000 usd
us-gaap Cash Acquired From Acquisition
CashAcquiredFromAcquisition
0 usd
us-gaap Cash Acquired From Acquisition
CashAcquiredFromAcquisition
3035000 usd
us-gaap Proceeds From Sale Of Intangible Assets
ProceedsFromSaleOfIntangibleAssets
0 usd
us-gaap Proceeds From Sale Of Intangible Assets
ProceedsFromSaleOfIntangibleAssets
15000000 usd
us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
0 usd
us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
475000 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-182741000 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-73121000 usd
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
11760000 usd
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
0 usd
syre Payment For Deferred Offering Costs
PaymentForDeferredOfferingCosts
78000 usd
syre Payment For Deferred Offering Costs
PaymentForDeferredOfferingCosts
usd
us-gaap Payments For Derivative Instrument Financing Activities
PaymentsForDerivativeInstrumentFinancingActivities
1430000 usd
us-gaap Payments For Derivative Instrument Financing Activities
PaymentsForDerivativeInstrumentFinancingActivities
0 usd
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
6203000 usd
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
123000 usd
us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
0 usd
us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
16000 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
185305000 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
197471000 usd
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
12000 usd
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
7000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-117635000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
55483000 usd
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
189215000 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
36416000 usd
CY2024Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
71580000 usd
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
91899000 usd
syre Exchange Of Stock Amount Exchanged
ExchangeOfStockAmountExchanged
38502000 usd
syre Exchange Of Stock Amount Exchanged
ExchangeOfStockAmountExchanged
0 usd
us-gaap Conversion Of Stock Amount Converted1
ConversionOfStockAmountConverted1
244010000 usd
us-gaap Conversion Of Stock Amount Converted1
ConversionOfStockAmountConverted1
0 usd
syre Deferred Offering Costs Allocated Amount Of Proceeds Of Issuance Of Common Stock
DeferredOfferingCostsAllocatedAmountOfProceedsOfIssuanceOfCommonStock
10000 usd
syre Deferred Offering Costs Allocated Amount Of Proceeds Of Issuance Of Common Stock
DeferredOfferingCostsAllocatedAmountOfProceedsOfIssuanceOfCommonStock
0 usd
CY2024Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
71580000 usd
CY2023Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
90592000 usd
CY2024Q3 us-gaap Restricted Cash
RestrictedCash
0 usd
CY2023Q3 us-gaap Restricted Cash
RestrictedCash
1307000 usd
CY2024Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
71580000 usd
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
91899000 usd
us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1 segment
CY2023Q2 us-gaap Restructuring And Related Cost Number Of Positions Eliminated Period Percent
RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent
0.83
CY2023Q4 us-gaap Temporary Equity Par Or Stated Value Per Share
TemporaryEquityParOrStatedValuePerShare
0.0001
syre Proceeds From Raising Capital
ProceedsFromRaisingCapital
1100000000 usd
CY2024Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-916100000 usd
CY2024Q3 us-gaap Marketable Securities
MarketableSecurities
414200000 usd
us-gaap Prior Period Reclassification Adjustment Description
PriorPeriodReclassificationAdjustmentDescription
<div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Reclassification of Prior Year Presentation</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain prior year amounts have been reclassified for consistency with the current year presentation. These reclassifications had no effect on the reported results of operations or balance sheets.</span></div>
CY2024Q3 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
69900000 usd
CY2024Q3 syre Cash Equivalents Unrealized Gains
CashEquivalentsUnrealizedGains
0 usd
CY2024Q3 syre Cash Equivalents Unrealized Losses
CashEquivalentsUnrealizedLosses
0 usd
CY2024Q3 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
69900000 usd
CY2024Q3 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
341246000 usd
CY2024Q3 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
1421000 usd
CY2024Q3 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
20000 usd
CY2024Q3 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
342647000 usd
CY2023Q4 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
186563000 usd
CY2023Q4 syre Cash Equivalents Unrealized Gains
CashEquivalentsUnrealizedGains
6000 usd
CY2023Q4 syre Cash Equivalents Unrealized Losses
CashEquivalentsUnrealizedLosses
0 usd
CY2023Q4 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
186569000 usd
CY2023Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
150101000 usd
CY2023Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
284000 usd
CY2023Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
1000 usd
CY2023Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
150384000 usd
CY2024Q3 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
37570000 usd
CY2024Q3 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
20000 usd
CY2024Q3 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
0 usd
CY2024Q3 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Accumulated Loss
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
0 usd
CY2024Q3 us-gaap Debt Securities Available For Sale Unrealized Loss Position
DebtSecuritiesAvailableForSaleUnrealizedLossPosition
37570000 usd
CY2024Q3 us-gaap Debt Securities Available For Sale Unrealized Loss Position Accumulated Loss
DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
20000 usd
CY2023Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
14738000 usd
CY2023Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
1000 usd
CY2023Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
0 usd
CY2023Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Accumulated Loss
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
0 usd
CY2023Q4 us-gaap Debt Securities Available For Sale Unrealized Loss Position
DebtSecuritiesAvailableForSaleUnrealizedLossPosition
14738000 usd
CY2023Q4 us-gaap Debt Securities Available For Sale Unrealized Loss Position Accumulated Loss
DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
1000 usd
CY2024Q3 syre Number Of Domestic Banking Institutions
NumberOfDomesticBankingInstitutions
2 bank
CY2024Q3 us-gaap Available For Sale Securities Debt Maturities Within One Year Fair Value
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
253613000 usd
CY2023Q4 us-gaap Available For Sale Securities Debt Maturities Within One Year Fair Value
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
115784000 usd
CY2024Q3 syre Debt Securities Available For Sale Fair Value Maturity Allocated And Single Maturity Date After Year One
DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearOne
89034000 usd
CY2023Q4 syre Debt Securities Available For Sale Fair Value Maturity Allocated And Single Maturity Date After Year One
DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearOne
34600000 usd
CY2024Q3 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
342647000 usd
CY2023Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
150384000 usd
CY2024Q3 us-gaap Accrued Salaries Current
AccruedSalariesCurrent
3966000 usd
CY2023Q4 us-gaap Accrued Salaries Current
AccruedSalariesCurrent
4054000 usd
CY2024Q3 syre Accrued Contracted Research And Development Costs
AccruedContractedResearchAndDevelopmentCosts
7527000 usd
CY2023Q4 syre Accrued Contracted Research And Development Costs
AccruedContractedResearchAndDevelopmentCosts
7092000 usd
CY2024Q3 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
1134000 usd
CY2023Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
1474000 usd
CY2024Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
526000 usd
CY2023Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
488000 usd
CY2024Q3 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
13153000 usd
CY2023Q4 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
13108000 usd
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
425500 shares
CY2024Q3 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
25.74
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
1044667 shares
CY2023Q3 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
14.50
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
1857853 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
28.40
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
3867366 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
9.65
CY2024Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
13100000 usd
CY2023Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
4785000 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
35617000 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
8405000 usd
CY2024Q3 us-gaap Share Based Compensation
ShareBasedCompensation
13100000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
35600000 usd
CY2023Q3 us-gaap Share Based Compensation
ShareBasedCompensation
4800000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
8400000 usd
CY2023Q4 us-gaap Contract With Customer Asset Net
ContractWithCustomerAssetNet
0 usd
CY2023Q4 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
0 usd
CY2024Q3 us-gaap Contract With Customer Asset Net
ContractWithCustomerAssetNet
0 usd
CY2024Q3 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
0 usd
CY2024Q3 us-gaap Weighted Average Number Of Shares Issued Basic
WeightedAverageNumberOfSharesIssuedBasic
50889433 shares
CY2023Q3 us-gaap Weighted Average Number Of Shares Issued Basic
WeightedAverageNumberOfSharesIssuedBasic
4015661 shares
us-gaap Weighted Average Number Of Shares Issued Basic
WeightedAverageNumberOfSharesIssuedBasic
44146958 shares
us-gaap Weighted Average Number Of Shares Issued Basic
WeightedAverageNumberOfSharesIssuedBasic
3116434 shares
CY2024Q3 us-gaap Incremental Common Shares Attributable To Call Options And Warrants
IncrementalCommonSharesAttributableToCallOptionsAndWarrants
0 shares
CY2023Q3 us-gaap Incremental Common Shares Attributable To Call Options And Warrants
IncrementalCommonSharesAttributableToCallOptionsAndWarrants
278151 shares
us-gaap Incremental Common Shares Attributable To Call Options And Warrants
IncrementalCommonSharesAttributableToCallOptionsAndWarrants
116788 shares
us-gaap Incremental Common Shares Attributable To Call Options And Warrants
IncrementalCommonSharesAttributableToCallOptionsAndWarrants
845112 shares
CY2024Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
50889433 shares
CY2024Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
50889433 shares
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
4293812 shares
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
4293812 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
44263746 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
44263746 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
3961546 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
3961546 shares
CY2023Q2 us-gaap Restructuring And Related Cost Number Of Positions Eliminated Period Percent
RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent
0.83
CY2023Q3 us-gaap Severance Costs1
SeveranceCosts1
0 usd
us-gaap Severance Costs1
SeveranceCosts1
6400000 usd
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Accelerated Compensation Cost
ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost
1000000.0 usd
CY2023Q2 us-gaap Disposal Group Including Discontinued Operation Consideration
DisposalGroupIncludingDiscontinuedOperationConsideration
500000 usd
CY2023Q2 us-gaap Operating Lease Impairment Loss
OperatingLeaseImpairmentLoss
900000 usd
CY2023Q2 us-gaap Impairment Of Leasehold
ImpairmentOfLeasehold
1700000 usd
CY2023Q3 syre Operating Lease Termination Fee Amount
OperatingLeaseTerminationFeeAmount
2000000.0 usd
CY2023Q4 syre Restructuring Cost Liability
RestructuringCostLiability
1100000 usd
CY2024Q3 syre Restructuring Cost Liability
RestructuringCostLiability
0 usd
CY2024Q3 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
CY2024Q3 ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
CY2024Q3 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false
CY2024Q3 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false

Files In Submission

Name View Source Status
syre-20240930_cal.xml Edgar Link unprocessable
0001636282-24-000083-index-headers.html Edgar Link pending
0001636282-24-000083-index.html Edgar Link pending
0001636282-24-000083.txt Edgar Link pending
0001636282-24-000083-xbrl.zip Edgar Link pending
ex104-spyrexfifthamendment.htm Edgar Link pending
ex105-spyrexofferletterssl.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
image_0a.jpg Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
spyre-20240930xex311.htm Edgar Link pending
spyre-20240930xex312.htm Edgar Link pending
spyre-20240930xex321.htm Edgar Link pending
syre-20240930.htm Edgar Link pending
syre-20240930.xsd Edgar Link pending
syre-20240930_g1.jpg Edgar Link pending
syre-20240930_g2.jpg Edgar Link pending
syre-20240930_g3.jpg Edgar Link pending
syre-20240930_g4.jpg Edgar Link pending
syre-20240930_g5.jpg Edgar Link pending
syre-20240930_g6.jpg Edgar Link pending
syre-20240930_g7.jpg Edgar Link pending
syre-20240930_def.xml Edgar Link unprocessable
syre-20240930_htm.xml Edgar Link completed
syre-20240930_lab.xml Edgar Link unprocessable
syre-20240930_pre.xml Edgar Link unprocessable